VCYT Veracyte
- 22.662
- +1.292+6.05%
Veracyte News
Veracyte's Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
Veracyte | 10-Q: Quarterly report
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
Veracyte Is Maintained at Buy by Needham
Veracyte Is Maintained at Buy by Needham
Veracyte Price Target Cut to $27.00/Share From $33.00 by Needham
Veracyte Price Target Cut to $27.00/Share From $33.00 by Needham
Needham Maintains Buy on Veracyte, Lowers Price Target to $27
Needham analyst Mike Matson maintains Veracyte with a Buy and lowers the price target from $33 to $27.
Veracyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 20.54% Needham $33 → $27 Maintains Buy 04/15/2024 25% Goldman Sachs $32 → $28 Maintains Buy 02/
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Maintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward Profitability
Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start With Revenue ...
Veracyte Q1 2024 GAAP EPS $(0.02) Beats $(0.17) Estimate, Sales $96.844M Beat $93.370M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.24 percent. This is a 81.82 percent increase over losses of $(0.11) per
Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts With Strong Test Performance
CRUS, ZI and VCYT Are Among After Hour Movers
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, Vs. Street Est of $93.4M
04:26 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M
Veracyte Now Expects Cash, Cash Equivalents and Short-Term Investments at the End of the Yr to Be $236M-$240M >VCYT
Veracyte Now Expects Cash, Cash Equivalents and Short-Term Investments at the End of the Yr to Be $236M-$240M >VCYT
Veracyte Raises 2024 View To Rev $402M-$410M >VCYT
Veracyte Raises 2024 View To Rev $402M-$410M >VCYT
Press Release: Veracyte Announces First Quarter 2024 Financial Results
Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH
Veracyte 1Q Loss $1.86M >VCYT
Veracyte 1Q Loss $1.86M >VCYT
Analysis
Price Target
No Data
